Participating Companies

Abliva Ab [ABLI:ST] SKr270 MM MCap
Fo­cused on rare and se­vere pri­mary mi­to­chon­drial dis­eas­es (PMD). KL1333, a NAD+ reg­u­la­tor, to ac­cel­er­ate in­to piv­o­tal studies in 2H21 based on pos­i­tive FDA feed­back; ini­tial re­sults from Ph1b in PMD pa­tients exp. in 1Q21. NV354, an en­er­gy re­place­ment ther­a­py for Leigh Syn­drome, in IND-en­abling studies. [more in­for­ma­tion]
AcelRx Pharmaceuticals, Inc. [ACRX] $78 MM MCap
Launched DSU­VIA (sufen­tanil sublin­gual tablet 30 mcg) in the US in 2019 for acute pain se­vere enough to re­quire opi­oid anal­gesic (adult pa­tients in cer­ti­fied med­i­cal­ly su­per­vised health­care sett­ings). Al­so de­vel­op­ing Za­lvi­so (Ph 3 com­plet­ed) in the US as an in­no­va­tive pa­tient-con­trolled anal­ge­sia sys­tem for mod­er­ate-to-se­vere acute pain in med­i­cal­ly su­per­vised sett­ings. [more in­for­ma­tion]
Affibody
Pro­pri­e­tary Af­fi­body® molecules and Al­bu­mod® plat­forms. Lead can­di­date ABY-035 is an IL-17 with mul­ti­ple Ph 2 pro­grams (PSO OLE PsA, axS­pA, uvei­tis). Pos­i­tive Ph2 52wk da­ta in pso­ri­a­sis with 2-yr OLE da­ta ex­pect­ed in 2H21. Ph2 in­ter­im da­ta for uvei­tis ex­pect­ed in 2022. AB-251 is a di­ag­nos­tic imag­ing pro­gram that is di­rect­ed pri­mar­i­ly to­wards me­tastat­ic breast can­cer. $81M raised to date. [more in­for­ma­tion]
Affimed N.V. [AFMD] $809 MM MCap
NK cell en­gager AFM13 (CD30/CD16A) en­rolling in a Phase 2 reg­is­tra­tion study in CD30-pos­i­tive pe­ripher­al T cell lym­pho­ma and an in­vesti­ga­tor-spon­sored study by MDACC of AFM13 com­bined with al­lo­gene­ic NK cells in re­lapsed/re­frac­to­ry CD30-pos­i­tive lym­pho­ma. [more in­for­ma­tion]
Alladapt Immunotherapeutics, Inc.
De­vel­op­ing a po­ten­tial­ly best-in-class oral im­munother­a­py that ad­dress­es a broad range of food al­ler­gies. AD­P101, which is cur­rent­ly in a Ph 1/2 clin­i­cal trial, is de­signed to de­sen­si­tize pa­tients al­ler­g­ic to one or to mul­ti­ple foods si­mul­ta­ne­ous­ly to miti­gate the risk of se­vere, life-threat­en­ing al­ler­g­ic re­ac­tions. The Com­pany was co-found­ed by Dr. Kari Nadeau, a renowned food al­ler­gist, and former 23andMe ex­ec, Ash­ley Dom­bkows­ki who serves as Al­la­dapt’s CEO. To date, the com­pany has raised $63 mil­lion. [more in­for­ma­tion]
Aptorum Group [APM] $67 MM MCap
Hong Kong based, US list­ed com­pany fo­cused on gen­er­at­ing late stage clin­i­cal can­di­dates by de­vel­op­ing al­ready ap­proved drugs for new or­phan in­di­ca­tions, as well as in­fec­tious dis­eas­es. [more in­for­ma­tion]
AsclepiX Therapeutics
Oph­thal­mol­o­gy com­pany us­ing com­pu­ta­tio­n­al bi­ol­o­gy to iden­ti­fy po­tent pep­tide reg­u­la­tors of vas­cu­lar home­os­ta­sis. The lead clin­i­cal can­di­date, in­te­grin reg­u­lat­ing pep­tide AX­T107 (ger­sizan­gi­tide), has a nov­el mech­anism of ac­tion that in­hibits neo­vas­cu­lariza­tion, re­duces vas­cu­lar perme­a­bil­i­ty and sup­press­es in­flam­ma­tion. In June 2020, Per­cep­tive Xon­toge­ny Ven­ture Fund led the $35 mil­lion Se­ries A fi­nanc­ing with par­ti­ci­pa­tion from ex­ist­ing in­ves­tors Rapha Cap­i­tal Ma­n­age­ment and Bar­er & Son Cap­i­tal. [more in­for­ma­tion]
Assembly Biosciences, Inc. [ASMB] $107 MM MCap
A pi­oneer in the de­vel­op­ment of a new class of po­tent, oral core in­hibi­tor drug can­di­dates, As­sem­b­ly Bio’s ap­proach aims to break the com­plex vi­ral re­pli­ca­tion cy­cle of HBV to free pa­tients from a life­time of ther­a­py. As­sem­b­ly Bio’s strat­e­gy to­ward cure in­cludes a lead­ing port­fo­lio of more po­tent, next-gen­er­a­tion core in­hibi­tors, proof-of-con­cept com­bi­na­tion studies and a re­search pro­gram fo­cused on the dis­cov­ery of nov­el HBV tar­gets, in­clud­ing cc­cD­NA dis­rup­tors and two other undis­closed mech­anisms. In 202 [more in­for­ma­tion]
AxoGen [AXGN] $392 MM MCap
Glob­al lead­er in de­vel­op­ment and mar­ket­ing of in­no­va­tive sur­g­i­cal so­lu­tions for the pe­ripher­al nerve in­jury mar­ket. Gui­dance for 2021 rev­enue is $127M-$129M with ex­pect­ed 2021 Gross Mar­gin re­main­ing above 80%. Lead prod­uct Avance Nerve Graft is a pro­cessed, hu­man al­lo­graft for bridg­ing nerve gaps of up to 70 mm. [more in­for­ma­tion]
Be Biopharma
Be Bio­phar­ma is a lead­er in de­vel­op­ing B cells as medicines, treat­ing dis­ease with the hu­man body’s na­tive pro­tein fac­to­ries. We pre­cise­ly en­gi­neer B cells to har­ness their in­trin­sic drug-like prop­er­ties – re­mark­able pro­tein pro­duc­tion, se­lec­tive tis­sue tar­get­ing, and fine con­trol of their cel­lu­lar en­vi­ron­ment – to forge a new cat­e­go­ry of cell ther­a­py. Be Bio was found­ed in Oc­to­ber 2020 by Long­wood Fund with a $52 mil­lion Se­ries A in­vest­ment led by At­las Ven­tures and RA Cap­i­tal, joined by Al­ta Part­n­ers and [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] $7,337 MM MCap
Com­mer­cial-stage, fo­cused on neu­ro­log­i­cal & neu­ropsychi­a­tric dis­eas­es; CGRP re­cep­tor an­ta­g­on­ist, glu­ta­mate mo­d­u­la­tion, and MPO plat­forms. NURTEC® ODT ap­proved 1Q20 acute treat­ment of mi­graine and 1Q21 pre­ven­tive treat­ment of mi­graine; $136m 3Q21 rev­enues. [more in­for­ma­tion]
BioShin
Whol­ly owned sub­si­diary of Bio­haven Phar­ma­ceu­ti­cals. Shang­hai-based, led by ex-BMY ex­ec and Bio­haven’s Chief of Corp Strat­e­gy & BD, Don­nie Mc­Grath, Bioshin aims to de­vel­op and com­mer­cial­ize Bio­haven’s late-stage mi­graine and neu­rol­o­gy port­fo­lio in Chi­na and other APAC mar­kets. [more in­for­ma­tion]
CASI Pharmaceuticals Inc. [CASI] $121 MM MCap
Launched EVOMELA® (mel­pha­lan for in­jec­tion, mul­ti­ple myelo­ma) in Au­gust '19, on­ly mel­pha­lan com­mer­cial­ly avai­l­able in Chi­na: $7.1M 2Q21 rev­enues/guid­ing FY 2020 of over 80% growth. Co-com­mer­cial as­set CNCT-19/CD19 CAR-T (part­nered w/ Ju­ven­tas): on­go­ing Ph 2 trials in B-NHL and B-ALL. Dosed 1st pa­tient in Ph 1 study for CID-103 (an­ti-CD38 mAb) in EU in June 2021. [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. [CPRX] $722 MM MCap
Fir­dapse ap­proved for Lam­bert-Ea­ton Myas­thenic Syn­drome (LEMS) with 3Q20 rev­enue of $29.2M. Top SMA Type 3 proof of con­cept trial ex­pect­ed to read­out by YE 2020. Fir­dapse long act­ing for­mu­la­tion de­vel­op­ment cont­in­ues. Studies for 2 ad­di­tio­n­al neu­ro­mus­cu­lar in­di­ca­tions are ex­pect­ed to com­mence by YE 2020. [more in­for­ma­tion]
Celularity [CELU] $790 MM MCap
Celu­lar­i­ty, head­quar­tered in Florham Park, NJ, is a clin­i­cal-stage biotech­nol­o­gy com­pany fo­cus­ing on cel­lu­lar medicine by de­vel­op­ing off-the-shelf pla­cen­tal-de­rived al­lo­gene­ic cell ther­a­pies. Celu­lar­i­ty has a her­i­tage as a former cell-ther­a­py busi­ness unit of Cel­gene. [more in­for­ma­tion]
Clerio Vision, Inc.
Nov­el oph­thalmic tech­nol­o­gy to treat re­frac­tive er­ror ad­dress­ing mul­ti-bil­lion mar­kets in con­tact lens­es (pres­by­opia, astig­ma­tism, my­opia, my­opia pro­gres­sion) and corneal vi­sion cor­rec­tion (non sur­g­i­cal fla­p­less las­er so­lu­tion). Pres­by­opia con­tact lens 510k sub­mis­sion 2022. Based on No­bel Prize win­n­ing fem­to-se­cond las­er tech­nol­o­gy de­vel­oped by Bausch & Lomb and the Uni­ver­si­ty of Roch­ester. [more in­for­ma­tion]
Corium, Inc.
Co­ri­um is a com­mer­cial-stage bio­phar­ma­ceu­ti­cal com­pany that is lead­ing the de­vel­op­ment and com­mer­cial­iza­tion of cen­tral ner­vous sys­tem (CNS) health care ther­a­pies that pro­vide clini­cians with im­por­tant treat­ment op­tions for pa­tients, their fam­i­lies and their care­givers. [more in­for­ma­tion]
Delcath Systems, Inc. [DCTH] $73 MM MCap
In­ter­ven­tio­n­al on­col­o­gy com­pany fo­cused on the treat­ment of pri­mary and me­tastat­ic liv­er can­cers. Com­pany’s pro­pri­e­tary per­cu­ta­neous he­p­at­ic per­fu­sion (PHP) sys­tem is de­signed to ad­min­is­ter high-dose che­mother­a­py to the liv­er while con­trolling sys­temic ex­po­sure and as­so­ci­at­ed side ef­fects. In the U.S., the PHP sys­tem is be­ing de­vel­oped un­der the tra­de­name HEP­ZA­TO KIT or HEP­ZA­TO, and is con­sid­ered a com­bi­na­tion drug and de­vice prod­uct reg­u­lat­ed by the FDA. [more in­for­ma­tion]
DURECT Corporation [DRRX] $225 MM MCap
Fo­cused on ad­vanc­ing nov­el and po­ten­tial­ly life­sav­ing in­vesti­ga­tio­n­al ther­a­pies de­rived from its Epi­ge­net­ic Reg­u­la­tor Pro­gram. Lead com­pound, DUR-928, has been grant­ed FDA Fast Track Desig­na­tion for al­co­hol-as­so­ci­at­ed he­p­ati­tis (AH) and is be­ing eval­u­at­ed in NASH with pos­i­tive to­p­line Ph 1b da­ta. [more in­for­ma­tion]
ESSA Pharma Inc. [EPIX] $388 MM MCap
Fo­cused on de­vel­op­ing nov­el ther­a­pies for the treat­ment of pros­tate can­cer. ES­SA’s lead clin­i­cal can­di­date, EPI-7386 is an in­vesti­ga­tio­n­al, high­ly-se­lec­tive, oral, small molecule in­hibi­tor of the N-ter­mi­nal do­main of the an­dro­gen re­cep­tor, with Ph 1 monother­a­py da­ta ex­pect­ed in 1H 2022. The com­pany has al­so estab­lished clin­i­cal col­lab­o­ra­tions with JNJ, Astel­las, and Bay­er. [more in­for­ma­tion]
Galera Therapeutics [GRTX] $35 MM MCap
Clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany fo­cus­ing on trans­form­ing ra­dio­ther­a­py in can­cer. Fi­nal da­ta with 1 year+ fol­low up on all pa­tients for GC4419 in pan­cre­at­ic can­cer an­nounced in 3Q21. To­p­line da­ta from GC4711 in NS­CLC ex­pect­ed in 1H22. To­p­line da­ta from GC4711 in NS­CLC ex­pect­ed in 1H22. [more in­for­ma­tion]
Genfit SA [GNFT] $149 MM MCap
De­vel­op­ment of po­ten­tial liv­er dis­ease treat­ment: ela­fi­branor in PBC: on­go­ing en­roll­ment for Ph 3 clin­i­cal trial EL­A­TIVE, fol­low-on PSC in­di­ca­tion. Com­mer­cial­iza­tion of NIS4™ for NASH di­ag­no­sis [more in­for­ma­tion]
Geron Corporation [GERN] $476 MM MCap
Fo­cused on the de­vel­op­ment and po­ten­tial com­mer­cial­iza­tion of a first-in-class telom­erase in­hibi­tor, ime­tel­s­tat, in myeloid he­ma­to­log­ic ma­lig­nan­cies. Geron is cur­rent­ly con­duct­ing two on­go­ing reg­is­tra­tion-en­abling Ph 3 clin­i­cal trials: (i) IMerge Phase 3 in Low or In­ter­me­di­ate-1 risk myelodys­plas­tic syn­dromes, or low­er risk MDS, and (ii) IM­pactMF in In­ter­me­di­ate-2 or High-risk myelo­fi­bro­sis, or re­frac­to­ry MF. Geron ex­pects top-line re­sults for IMerge Phase 3 to be avai­l­able at the be­gin­n­ing of Jan­uary 2023. [more in­for­ma­tion]
Heidelberg Pharma AG [HPHA:DB] €177 MM MCap
Hei­del­berg Phar­ma AG (HPHA, Frank­furt Stock Exchange), based in La­den­burg, Ger­many, is a lead­ing biotech com­pany pi­oneer­ing the use of its AT­AC (Anti­body Tar­get­ed Amanitin Con­ju­gate) plat­form to de­vel­op nov­el can­cer treat­ments with a unique mode of ac­tion ef­fec­tive at spe­cif­i­cal­ly killing both in­ac­tive and di­vid­ing can­cers cells and over­com­ing tu­mor re­sis­tance mech­anisms. [more in­for­ma­tion]
Humanigen Inc. [HGEN] $355 MM MCap
Ad­di­tio­n­al clin­i­cal de­vel­op­ment for lenzilumab in­cludes as a treat­ment for cy­tokine storm as­so­ci­at­ed with CD19-tar­get­ed CAR-T cell ther­a­pies and ex­plor­ing ef­fec­tive­ness of lenzilumab in other in­flam­ma­to­ry con­di­tions. [more in­for­ma­tion]
ImmuneSensor, LLC
Im­mu­ne­Sen­sor is a ther­a­peu­tic in­nate im­mu­ni­ty com­pany de­vel­op­ing drugs tar­get­ing the cGAS-ST­ING path­way for the treat­ment of can­cer and au­toim­mune dis­eas­es. The com­pany pipe­line in­cludes a clin­i­cal stage ST­ING ag­on­ist cur­rent­ly in an ICI com­bi­na­tion trial, with the po­ten­tial of en­ter­ing Phase 2 de­vel­op­ment in 2022; [more in­for­ma­tion]
Immunocore [IMCR] $1,450 MM MCap
Pi­oneer­ing the de­vel­op­ment of a nov­el class of T cell re­cep­tor (TCR) bis­pe­cif­ic im­munother­a­pies de­signed to treat a broad range of dis­eas­es, in­clud­ing can­cer, in­fec­tious and au­toim­mune dis­ease. MAGE-A4 Phase 1 Da­ta Q4 2021, tebenta­fusp PD­U­FA tar­get ac­tion date Feb. 2022, PRAME Phase 1 Da­ta Mid-2022. [more in­for­ma­tion]
Impact Therapeutics Inc
IM­PACT Ther­a­peu­tics is a pri­vate­ly held clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany and ded­i­cat­ed to the dis­cov­ery and de­vel­op­ment of tar­get­ed an­ti-can­cer ther­a­peu­tics based on syn­thet­ic lethal­i­ty. IM­P7068 is a nov­el Wee1 in­hibi­tor dis­cov­ered and de­vel­oped by IM­PACT Ther­a­peu­tics, with world­wide in­tel­lec­tu­al prop­er­ty, part of in-house DDR franchise. [more in­for­ma­tion]
IN8bio, Inc. [INAB] $110 MM MCap
First com­pany to ad­vance ge­net­i­cal­ly-mod­i­fied gam­ma-del­ta T cells in­to clin­i­cal trials with its Del­tEx Plat­form, based on ex-vi­vo ex­pand­ed and ac­ti­vat­ed gam­ma-del­ta T cells. Two in­vesti­ga­tor-ini­ti­at­ed Phase 1 clin­i­cal trials are un­der­way for lead prod­uct can­di­dates: INB-200 for new­ly di­ag­nosed glioblas­to­ma and INB-100 for acute leukemia. [more in­for­ma­tion]
Invetx
In­vetx is build­ing the world’s pre­mi­er biotech­nol­o­gy plat­form for pro­tein-based ther­a­peu­tics in an­i­mal health to trans­form stan­dards of care in ve­t­eri­nary medicine. The In­vetx team of high­ly ex­pe­ri­enced R&D lead­ers from both hu­man biotech and an­i­mal health is sup­port­ed by best-in-class biotech­nol­o­gy part­n­ers and an ex­ten­sive net­work of in­dus­try ex­perts, ve­t­eri­nary sci­en­tists and clini­cians. In­vetx is a pri­vate com­pany head­quar­tered in Bos­ton, Mas­sachusetts. [more in­for­ma­tion]
Iovance Biotherapeutics [IOVA] $2,758 MM MCap
De­vel­op­ing nov­el can­cer im­munother­a­pies based on tu­mor in­fil­trat­ing lym­pho­cytes (TIL) for the treat­ment of solid tu­mors. TIL ther­a­py is a high­ly per­so­n­al­ized ap­proach in which pa­tients re­ceive a one-time treat­ment with their own ex­pand­ed and re­ju­ve­nat­ed T-cells to treat can­cer. BLA ex­pect­ed in 1H22 fol­low­ing com­ple­tion of piv­o­tal study of Li­fileu­cel/LN-144 for treat­ment of Me­lano­ma. [more in­for­ma­tion]
Junshi Biosciences [1877:HK]
Has a di­ver­si­fied R&D pipe­line com­pris­ing over 21 drug can­di­dates with ther­a­peu­tic ar­eas cov­er­ing can­cer, metabolic, au­toim­mune, neu­ro­log­i­cal, and in­fec­tious dis­eas­es. Lead can­di­date, Tori­pal­imab (JS001), reached over 1B RMB in sales, and ex­pand­ed in­di­ca­tions in­to na­sopha­ryn­geal car­ci­no­ma/urothe­lial car­ci­no­ma. Other prod­uct types in­clude mon­o­clo­n­al anti­bodies, fu­sion pro­teins, anti­body-drug con­ju­gates, and small molecule drugs. With a com­bined 33,000L fer­men­ta­tion ca­pac­i­ty in two GMP-fa­cil­i­ties at Shang­hai [more in­for­ma­tion]
KBio
KBio is cre­at­ing the new gen­er­a­tion of bi­o­log­ics us­ing its plant-based plat­form that has de­mon­s­trat­ed an abil­i­ty to cre­ate po­ten­tial­ly bet­ter anti­body drug can­di­dates at a frac­tion of the time and cost of cur­rent mam­malian cell-based anti­body plat­forms. The Com­pany is fo­cused on de­vel­op­ing nov­el prod­uct can­di­dates in two core ar­eas: 1) Anti­body ther­a­pies for ar­eas of high un­met need 2) Pan­dem­ic pre­pared­ness and re­sponse us­ing its plant-based pro­duc­tion sys­tem to rapid­ly cre­ate anti­bodies and vaccines. [more in­for­ma­tion]
Keros Therapeutics [KROS] $1,305 MM MCap
A lead­er in un­der­s­tand­ing the role of the TGF-Be­ta fam­i­ly of pro­teins that is a mas­ter reg­u­la­tor of RBC and platelet pro­duc­tion as well as the growth, re­pair and main­te­nance of mus­cle and bone. Lead pro­tein ther­a­peu­tic prod­uct can­di­date, KER-050, is be­ing de­vel­oped for the treat­ment of cy­tope­nias, in­clud­ing ane­mia and throm­bo­cy­tope­nia, in pa­tients with myelodys­plas­tic syn­drome (MDS) and myelo­fi­bro­sis, with ad­di­tio­n­al da­ta ex­pect­ed from Part 1 of Ph 2 study in MDS be­ing pre­sent­ed at ASH 2021. [more in­for­ma­tion]
Kintor Pharma [9939-hk]
Two Ph3s on­go­ing in Chi­na: Piv­o­tal monother­a­py and com­bo with abi­raterone and a Ph2 on­go­ing in US for mCR­PC (with breast and other AR-driv­en can­cers be­hind). Ad­di­tio­n­al pipe­line in­cludes a top­i­cal AR for alope­cia and ear­li­er-stage tar­gets in­clud­ing ALK-1 and hedge­hog. [more in­for­ma­tion]
Lineage Cell Therapeutics Inc. [LCTX] $320 MM MCap
Cell ther­a­py com­pany with 3 clin­i­cal pro­grams 1) OpRe­gen, an RPE tran­s­plant ther­a­py in Ph1/2a de­vel­op­ment for the treat­ment of dry-AMD. 2) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py for acute spi­nal cord in­juries with Or­phan and RMAT desig­na­tions. 3) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in a Ph 1 for NS­CLC con­duct­ed by CRUK. [more in­for­ma­tion]
Longboard Pharmaceuticals [LBPH] $96 MM MCap
Fo­cused on de­vel­op­ing nov­el, trans­for­ma­tive medicines for neu­ro­log­i­cal dis­eas­es, with an ini­tial fo­cus on rare dis­eas­es. Long­board is cur­rent­ly eval­u­at­ing LP352, an oral, cen­tral­ly act­ing, next-gen­er­a­tion 5-hy­drox­ytryp­tamine 2c re­cep­tor su­per­a­g­on­ist, for the treat­ment of epilep­tic seizures. Long­board is al­so eval­u­at­ing a cann­abi­noid type 2 (CB2) re­cep­tor ag­on­ist for treat­ment of neu­rode­gen­er­a­tive dis­eas­es, and a sphin­go­sine-1-phos­phate (S1P) re­cep­tor mo­d­u­la­tor for treat­ment of neu­roin­flam­ma­to­ry dis­eas­es. [more in­for­ma­tion]
Marker Therapeutics [MRKR] $98 MM MCap
Fo­cused on de­vel­op­ing next-gen­er­a­tion T cell-based im­munother­a­pies for the treat­ment of he­ma­to­log­i­cal ma­lig­nan­cies and solid tu­mor in­di­ca­tions. Mark­er's cell ther­a­py tech­nol­o­gy is based on the se­lec­tive ex­pan­sion of non-en­gi­neered, tu­mor-spe­cif­ic T cells that rec­og­nize tu­mor as­so­ci­at­ed anti­gens and kill tu­mor cells ex­press­ing those tar­gets. [more in­for­ma­tion]
MiNA Therapeutics
Ver­satile, pro­pri­e­tary small ac­ti­vat­ing ri­bonu­cle­ic acid (saR­NA) ther­a­peu­tics plat­form and in­ter­nal pipe­line, ini­tial­ly fo­cus­ing on on­col­o­gy and rare dis­ease in­di­ca­tions. Ini­ti­at­ing ran­domized Ph2 study for lead saR­NA drug can­di­date MTL-CEB­PA com­bined with so­rafenib in 2L HCC in 4Q21. $1.5B+ phar­ma part­n­er­ships. [more in­for­ma­tion]
Monte Rosa Therapeutics [GLUE] $810 MM MCap
Next-gen­er­a­tion molec­u­lar glue-based tar­get­ed pro­tein degra­da­tion plat­form de­vel­op­ing small molecule ther­a­peu­tics that se­lec­tive­ly de­grade dis­ease-caus­ing pro­teins. Tar­get­ing the un­drug­gable pro­teome in on­col­o­gy and non-on­col­o­gy in­di­ca­tions via AI based de­gron pre­dic­tion. Lead pro­gram fo­cused on GSP­T1, a key reg­u­la­tor and vul­n­er­a­bil­i­ty of Myc-in­duced trans­la­tio­n­al ad­dic­tion. [more in­for­ma­tion]
Neogene Therapeutics
Neo­gene’s nov­el ap­proach in­tends to de­liv­er a tailored set of TCR genes for each in­di­vi­d­u­al pa­tient, which will be en­gi­neered in­to pa­tient-de­rived T cells di­rect­ing them to­ward neo-anti­gens in tu­mor cells, with the goal of pro­vid­ing a ful­ly in­di­vi­d­u­al­ized en­gi­neered T cell ther­a­py for can­cer. The Com­pany raised a $110M Se­ries A fi­nanc­ing co-led by EcoR1 Cap­i­tal, Jei­to Cap­i­tal and Syn­co­na, with par­ti­ci­pa­tion from Po­laris Part­n­ers, Pon­ti­fax, Seed in­ves­tors, Vi­da Ven­tures, TPG and Two Riv­er. [more in­for­ma­tion]
Neoleukin Therapeutics [NLTX] $206 MM MCap
Its lead prod­uct can­di­date, NL-201, is a com­bined IL-2 and IL-15 ag­on­ist de­signed to im­prove tol­er­a­bil­i­ty and ac­tiv­i­ty by elim­i­nat­ing the al­pha re­cep­tor bind­ing in­ter­face. NL-201 is cur­rent­ly be­ing eval­u­at­ed in a Phase 1 clin­i­cal trial in pa­tients with re­lapsed or re­frac­to­ry can­cer and the com­pany is ex­pect­ing in­ter­im da­ta in 2022. [more in­for­ma­tion]
NorthSea Therapeutics
First-in class, oral, struc­tu­ral­ly en­gi­neered fat­ty acids [SE­FAs] ad­dress­ing NASH (pos­i­tive Ph2b in­ter­im re­sults) and as­so­ci­at­ed metabolic di­s­or­ders via unique tar­get­ing of path­ways reg­u­lat­ing metabolism, oxida­tive stress, in­flam­ma­tion, and fi­bro­sis. $40m Se­ries B (2020) with ven­Bio Part­n­ers (lead) and Sofin­no­va In­vest­ments. [more in­for­ma­tion]
Novavax AB [NVAX] $15,774 MM MCap
Clin­i­cal-stage vaccine com­pany lev­er­ag­ing re­com­bi­nant nano­par­ti­cle tech­nol­o­gy plat­form to ad­dress a broad range of in­fec­tious dis­eas­es. NVX-CoV­2373, lead vaccine can­di­date against SARS-CoV-2 is be­ing eval­u­at­ed in two piv­o­tal Ph 3 trials [more in­for­ma­tion]
Photocure ASA [PHO:OS] NKr2,614 MM MCap
Rev­enue-gen­er­at­ing urol­o­gy-fo­cused com­pany. Lead prod­uct, Hexvix®/Cysview® im­proves de­tec­tion of blad­der can­cer un­der blue light cys­tos­copy (BLC), which can re­duce dis­ease re­cur­rence and pro­gres­sion rates. Hexvix®/Cysview® is in­clud­ed in clin­i­cal consen­sus guide­lines and re­mains on a strong growth path. Rev­enues in 2020 to­taled $31M. Re­cent­ly suc­cess­ful­ly launched the Eu­ro­pean Hexvix op­er­a­tions, con­soli­dat­ing the Com­pany’s prod­uct franchise glob­al­ly. [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] $235 MM MCap
An­ti­calins (en­gi­neered lipo­calin pro­teins) for re­sp & IO. Phase 2a to­p­line da­ta for AZN-part­nered PRS-060 in­haled IL4 for mod-to-se­vere asth­ma next year. Cash of $125MM in the bank as of Sept 2021. [more in­for­ma­tion]
Redx Pharma [REDX]
Dis­cov­ers and de­vel­ops nov­el tar­get­ed medicines for the treat­ment of can­cer and fi­brot­ic dis­ease. Lead on­col­o­gy as­set, Por­cu­pine in­hibi­tor RX­C004, com­menced Ph2 in 4Q21. RX­C004 al­so in Ph1 com­bi­na­tion with an­ti-PD-1 anti­body nivolumab. ROCK2 in­hibi­tor, RX­C007, in de­vel­op­ment for idio­path­ic pul­mo­nary fi­bro­sis, ex­pect­ing re­sults in 2022. £39.9M in cash. Cash run­way un­til end 2022. ~$1BN in po­ten­tial mile­s­tone rev­enues. Sup­port­ed by Red­mile Group, Soffi­no­va Part­n­ers, Po­lar Cap­i­tal [more in­for­ma­tion]
Rigel Pharmaceuticals [RIGL] $457 MM MCap
Fo­cused on he­ma­to­log­ic di­s­or­ders, can­cer, and rare im­mune dis­eas­es. Rigel's first FDA ap­proved prod­uct is TA­VALISSE® (fos­ta­ma­tinib di­s­odi­um hex­ahy­drate) tablets, the on­ly oral spleen ty­ro­sine ki­nase in­hibi­tor for the treat­ment of chron­ic im­mune throm­bo­cy­tope­nia. The Com­pany is al­so tar­get­ing SYK in Warm Anti­body AI­HA and COVID-19, in­ter­leukin re­cep­tor-as­so­ci­at­ed ki­nas­es 1&4 in on­col­o­gy and im­mune dis­eas­es, and re­cep­tor-in­ter­act­ing serine/thre­o­nine-pro­tein ki­nase 1 in CNS dis­eas­es. [more in­for­ma­tion]
Savara Inc. [SVRA] $123 MM MCap
Clin­i­cal-stage bio­phar­ma fo­cused on rare re­s­pi­ra­to­ry dis­eas­es; mol­gra­mos­tim, an in­haled gran­u­lo­cyte-macrophage colony-sti­m­u­lat­ing fac­tor (GM-CSF), is in Phase 3 de­vel­op­ment for the treat­ment of au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP); top-line da­ta from the dou­ble-blind pe­ri­od of the Com­pany’s Phase 3 trial (IM­PALA 2) is an­ti­ci­pat­ed at the end of 2Q 2024. [more in­for­ma­tion]
Sigilon Therapeutics, Inc. [SGTX] $101 MM MCap
En­gi­neer­ing cells to pro­duce miss­ing pro­teins/en­zymes/etc; en­cap­su­late cells in pro­pri­e­tary sphere ma­trix (dev’d at Bob Langer's Lab at MIT) to pre­vent fi­bro­sis & im­mune re­jec­tion; 2 can­di­dates in clin­ic by year-end 2021 (SIG-001 in Hem A & SIG-005 in MPS-1); Eli Lil­ly col­lab­o­ra­tion in T1D ($75m ini­tial com­mit­ment, $410 mile­s­tones & sin­gle to dou­ble dig­it roy­al­ties) [more in­for­ma­tion]
Sonnet Biotherapeutics, Inc. [SONN] $32 MM MCap
Uti­l­iz­ing a plat­form ap­proach to de­vel­op im­muno-on­col­o­gy ther­a­peu­tics fea­tur­ing a pro­pri­e­tary ful­ly hu­man Al­bu­min Bin­der ca­pa­ble of link­ing 1-2 dif­fer­ent ther­a­peu­tic tar­gets. Son­net's in­ter­leukin-based can­di­date has been shown to en­hance pK (up to 10 fold) and im­prove tu­mor de­liv­ery with an in­crease in in vi­vo ef­fi­ca­cy (30 fold) as de­mon­s­trat­ed in a mice tu­mor mod­el. [more in­for­ma­tion]
Spruce Biosciences [SPRB] $57 MM MCap
Fo­cused on de­vel­op­ing and com­mer­cial­iz­ing nov­el ther­a­pies for rare en­docrine di­s­or­ders. The com­pany’s lead prod­uct can­di­date, Til­dac­er­font, is cur­rent­ly be­ing eval­u­at­ed for the treat­ment of clas­sic adult con­geni­tal adre­nal hy­per­pla­sia (CAH), and in up­com­ing studies in pe­di­a­tric clas­sic CAH and Po­ly­cys­tic Ovary Syn­drome (PCOS). [more in­for­ma­tion]
Sutro Biopharma [STRO] $731 MM MCap
Fo­cused on de­vel­op­ing next gen­er­a­tion anti­body drug con­ju­gates (ADCs) and other com­plex bi­o­log­ics for can­cer. The com­pany’s FolR&al­pha;-tar­get­ing ADC (STRO-002) in ovarian can­cer is cur­rent­ly in Ph 1 with dose-ex­pan­sion da­ta ex­pect­ed in 2H 2021. En­roll­ment is on­go­ing for CD74-tar­get­ing ADC (STRO-001) in the Ph 1 dose-es­ca­la­tion in B-cell ma­lig­nan­cies. Sutro has three high val­ue col­lab­o­ra­tions with BMS, Mer­ck, and EMD Serono. [more in­for­ma­tion]
Teon Therapeutics
Pipe­line of next-gen­er­a­tion can­cer ther­a­peu­tics tar­get­ing GPCRs in­clud­ing a high­ly-spe­cif­ic A2B an­ta­g­on­ist and EP4 an­ta­g­on­ist, both slat­ed to en­ter Phase 1b trials in 2021. [more in­for­ma­tion]
Treos Bio Limited
Pipe­line in­cludes per­so­n­al­ized + off-the-shelf ther­a­pies for mul­ti­ple solid can­cers and an IND-ready 2nd gen­er­a­tion COVID T-cell vaccine. Their lead pro­grams in­clude treat­ment for MSS col­orec­tal can­cer, with strong Ph 1/2 re­sults, and clin­i­cal col­lab­o­ra­tions with Roche and Mayo Clin­ic. Tre­os has $42M raised to date, with cur­rent in­ves­tors in­clud­ing BXR Group, Conor Fund Seed Cap­i­tal, Fu­ture Fund, Out­sized Ven­tures (former­ly Lu­mi­nous Ven­tures), SPRIM Ven­tures, and The Hop­kins Cap­i­tal Group. [more in­for­ma­tion]
Vaccitech Plc [VACC] $430 MM MCap
Pro­pri­e­tary ChA­dOx (prime) and MVA (boost) tech­nol­o­gy plat­form in­duces CD8+ T cell and anti­body im­mune re­spons­es to treat and pre­vent in­fec­tious dis­eas­es and can­cer. Broad ther­a­peu­tic pipe­line. En­cour­ag­ing Ph1/2 in­ter­im ef­fi­ca­cy da­ta for VTP-300 (HBV func­tio­n­al cure) and VTP-200 (high-risk HPV ther­a­peu­tic) ef­fi­ca­cy da­ta ex­pect­ed 1Q2022. Out-li­censed ChA­dOx COVID-19 vaccine mar­ket­ed by As­traZene­ca, rev­enue po­ten­tial 2022. [more in­for­ma­tion]
Verrica Pharmaceuticals [VRCA] $285 MM MCap
A der­ma­tol­o­gy ther­a­peu­tics com­pany de­vel­op­ing med­i­ca­tions for skin dis­eas­es re­quir­ing med­i­cal in­ter­ven­tions. Ver­ri­ca's lead prod­uct can­di­date, VP-102, is a GMP-con­trolled for­mu­la­tion of can­tharidin de­liv­ered via a sin­gle-use ap­pli­ca­tor for the treat­ment of mol­lus­cum con­ta­gio­sum (mol­lus­cum), com­mon warts and ex­ter­nal geni­tal warts. The Com­pany is al­so de­vel­op­ing treat­ments for plan­tar warts (VP-103) and basal cell car­ci­no­ma (LTX-315). [more in­for­ma­tion]
Vivoryon [VVY]
Fo­cused on nov­el small molecule in­hibi­tors of glu­taminyl cy­clase (QPCT) de­signed to pre­vent the for­ma­tion of patho­log­i­cal­ly al­tered pro­teins be­fore they cause ir­re­v­ersi­ble da­m­age. Lead can­di­date varog­lu­tam­s­tat, cur­rent­ly in Phase 2 in Alzheimer’s dis­ease (AD), tar­gets all three ma­jor hall­marks of AD. [more in­for­ma­tion]
XOMA Corporation [XOMA] $232 MM MCap
Biotech roy­al­ty and mile­s­tone ag­gre­ga­tor with port­fo­lio of 70+ as­sets in >30 dis­closed in­di­ca­tions where R&D costs are borne by part­n­ers e.g. Roche's Faricimab (BLA filed for nAMD and DME 7/29/21) [more in­for­ma­tion]
Zentalis [ZNTL] $3,326 MM MCap
De­vel­op­ing best-in-class small molecule ther­a­peu­tics tar­get­ing fun­da­men­tal bi­o­log­i­cal can­cer path­ways. WEE1 in­hibi­tor for ad­vanced solid tu­mors cur­rent­ly in Ph 2. ZN-c5, an oral SERD for breast can­cer, ZN-d5, a BCL-2 in­hibi­tor for he­ma­to­log­ic ma­lig­nan­cies, and ZN-e4, an EGFR in­hibi­tor for NS­CLC. [more in­for­ma­tion]